Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles
 

Open Access

23



Inhibition of dipeptidyl peptidase IV by fexofenadine: Virtual screening study

Ihab M. Almasri Mohammad K. Mohammad Mutasem O. Taha.

Abstract
Dipeptidyl peptidase IV (DPP IV) is relatively new anti-diabetic target. DPP IV inhibitors improve glycemic control by preventing rapid inactivation of the natural hypoglycemic incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. In this work, the high throughput docking software FRED was used as a virtual screening tool against in house built drug database to discover new DPP IV inhibitors. One of the highest ranking hits, the antihistamine drug fexofenadine, was found to inhibit recombinant human DPP IV in vitro with IC50 = 4.6 ( 1.0) M. The anti-diabetic effect of fexofenadine was validated in vivo by OGTT test. These results could be helpful in the development of novel DPP IV inhibitors based on fexofenadine scaffold for the treatment of type 2 diabetes.

Key words: Key words: Fexofenadine; DPP IV inhibition; Virtual screening; Docking; OGTT



Share this Article


Advertisement
Journal of Apitherapy

SUBMIT YOUR ARTICLE NOW


ScopeMed.com
ScopeMed Home
Follow ScopeMed on Twitter
BiblioCAM
Author Tools
eJPort Journal Hosting
About ScopeMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.
Scopemed Buttons